CBD Resource Center

The Important Role of the Endocannabinoid System and the Endocannabinoidome in Gut Health

The Endocannabinoid System and its Modulation by Cannabidiol (CBD)

Medical Marijuana, Inc. Announces Completion of the First-Ever High-Level Stability Study on a CBD Hemp Oil Product

Avoid Toxic CBD Products -- UrthLeaf Lab Results Confirm Products Free of Harmful Chemicals

Medical Marijuana, Inc. Announces Completion of the First-Ever High-Level Stability Study on a CBD Hemp Oil Product

 Medical Marijuana, Inc. (OTC: MJNA) (the "Company"), the first-ever publicly traded cannabis company in the United States that launched the world's first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that the Company has reached a major milestone for long-term stability testing on its flagship THC-free cannabidiol (CBD) oil product Real Scientific Hemp Oil-X™ (RSHO-X^TM). The stability study was conducted in strict compliance with FDA/ICH guidelines (Q1A-R2).   

"We're excited to offer consumers and retail partners the transparency and security of knowing that our products are reliable and stable throughout several climatic conditions and through transportation," said Medical Marijuana, Inc. CEO Dr. Stuart Titus. "Our company set the standards for many CBD testing protocols in the U.S. and intends to continue doing so with this study. Our customers strongly rely on the quality, potency and safety of RSHO-X, which has been tested in two successful pilot clinical studies. Therefore, we take it seriously to keep the quality standard criteria higher for our products and provide accurate and specific safety and expiration information."

"The results from the study provide significant evidence that RSHO-X has a shelf-life of at least 12 months at different and extreme climate conditions. This helps the company ensure to its customers and retailers that the integrity of the product will not be compromised while in transportation or while being stored for future use," said Medical Marijuana, Inc. Vice President of Project Analysis and R&D, Dr. Levan Darjania. "The purpose of this accelerated and long-term testing was to evaluate the stability profile of RSHO-X and to assess the product's performance and safety as well as the acceptability according to the FDA-ICH Guideline on stability testing."

The data obtained from this study also reveals indications about the behavior of RSHO-X™ over determined time intervals while facing the different environmental conditions to which it may be exposed from the production date until the end of its validity. The study was outsourced to one of the most qualified cGLP/cGMP compliant Contract Research Organizations (CROs) with attained ISO 17025 accreditation and certification.

During the course of the stability study, multiple samples of RSHO-X™ were exposed to various climatic zones associated environmental conditions covering the U.S., Europe, Mexico and Brazil. CBD quantitation tests were performed using fully validated, proprietary analytical UPLC-PDA and LC-MS/MS methods reflecting the specificity and selectivity toward RSHO-X™, including data elements and parameters such as accuracy, precision, repeatability, ruggedness, system suitability, linearity, specificity, dilution integrity and dynamic range. In addition to CBD monitoring and quantitation, the stability samples were tested for appearance, odor, specific gravity, viscosity, package compatibility and complete microbial test characteristics.

The test results showed that no change (more than 5%) in the CBD content and other specifications were observed and the container closure system was faultless at both long-term and accelerated test conditions.

The positive 6-month accelerated and 9-month long-term stability test results suggest that RSHO-X™ is a stable formulation. A preliminary shelf-life of 12 months was derived from the primary and supportive data. The stability testing will be continued up to 24 months. A corresponding shelf-life of 24 months is anticipated.

To learn more about the study or Medical Marijuana, Inc., please visit: www.medicalmarijuanainc.com.

About Medical Marijuana, Inc.
Medical Marijuana, Inc. (MJNA) is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space: a global portfolio of cannabinoid-based nutraceutical brands led by Kannaway® and HempMeds®; a pioneer in sourcing the highest-quality legal non-psychoactive cannabis products derived from industrial hemp; and a cannabinoid-based clinical research and botanical drug development sector led by its internal R&D and scientific team and its pharmaceutical investment companies and partners including AXIM® Biotechnologies, Inc. and Kannalife, Inc. .

To see Medical Marijuana, Inc.'s corporate video, click here.

Avoid Toxic CBD Products -- UrthLeaf Lab Results Confirm Products Free of Harmful Chemicals

With the rising trend of CBD products, fraudulent companies are being exposed for using harmful chemicals and dilutors in order to exploit this spike in popularity. This results in higher profit margins for these companies while leaving the consumer with a potentially dangerous product. However, not all companies are putting profit before people; UrthLeaf has been identified as a company that follows industry best practices by subjecting all of their products to rigorous lab testing. Knowing that it is important for their consumers to buy with confidence, UrthLeaf is excited to share the results from their most recent series of lab testing: free of harmful chemicals typically found in poor quality CBD.

In the past year alone, three companies have been blacklisted by the FDA for unruly business practices involving the manufacturing and sale of cannabidiol (CBD) products. In the past 5 years, a whopping 48 U.S. companies have been placed on this exact list, receiving warning letters from the FDA to either cease operations or comply with the laws and best practices that protect the consumer. The FDA effectively made it clear that there is no room for harmful products in the U.S. cannabidiol markets, yet companies continue to get away with these shady business practices on a daily basis.

As the "fear of missing out" creeps into the CBD market, consumers are unknowingly buying into these products while lacking the proper tools needed to identify the products most likely to contain harmful chemicals. With CBD tinctures having become the new craze in healthcare and medicine over the past few years, we take a look into what really goes into the products that have everyone ranting and raving. According to Leafly, a popular cannabis and cannabidiol publication outlet, two chemicals continue to appear time and time again in lab tests for certain CBD tinctures. These two chemicals are dextromethorphan (DXM) and 5F-ADB, which are two potentially lethal chemicals in high doses. Dextromethorphan is a very popular cough syrup known for its addictive and abusive behaviors, while 5F-ADB has a very similar chemical composition to the synthetic drug K2 (also popularly known as Spice). 

UrthLeaf firmly believes that the public should not be left in the dark about these toxic chemicals, which is why they have been completely transparent about every ingredient that goes into their products. In May 2019, thorough testing was performed on UrthLeaf's product line by Cannalysis (Santa Clara, CA), a CBD/THC testing lab. After multiple trials, it was determined that UrthLeaf's CBD line contains ZERO toxic chemicals and is truly 100% organic. No signs of DXM, 5F-ADB, or any other potentially harmful chemicals were found, but rather pure CBD derived naturally from hemp plants. 

So why isn't every company following in the footsteps of UrthLeaf? Why do companies still exist if they are selling potentially lethal products to unknowing consumers? How can these companies be stopped? Well, companies are doing it for one reason and one reason only: profits. It is much more profitable to dilute a CBD product with non-natural chemicals than it is to pursue the completely organic route.

It is strongly recommended that consumers research the ingredients in their CBD products before use since it is very difficult to see any short-term side effects by using pesticide or chemical-containing products, but the long term effects can potentially be deadly. The FDA is doing as much as they can to limit the number of dangerous companies entering this market, but ultimately it is up to the consumer to do their own research before deciding on which product to purchase.